**Supplementary Table 2.** HRs and 95% CIs for the incidence of myocardial infarction, stroke, and all-cause death during follow-up according to the ranges of LDL-C level, setting the LDL-C range with the lowest hazard as a reference

| Variable               | Ranges of LDL-C, mg/dL | HR (95% CI) in model 1 | HR (95% CI) in model 2 | HR (95% CI) in model 3 | HR (95% CI) in model 4 |
|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                        | LDL-C <55 (n=29,211)  |                        |                        |                        |                        |
| Myocardial infarction  |                        |                        |                        |                        |                        |
| No. of events          | 1,082                  | 1.01 (0.94–1.09)       | 1.01 (0.94–1.09)       | 0.97 (0.90–1.04)       | 0.98 (0.91–1.05)       |
| Follow-up duration, person-years | 212,710.81               | 2,056                  | 2,017                  | 2,000                  | 2,045                  |
| Incidence rate, /1,000 person-years | 5.09                       | 4.92                   | 4.78                   | 5.16                   | 5.73                   |
| HR (95% CI) in model 1 |                        | 1.17 (1.12–1.23)       | 1.09 (1.04–1.11)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       |
| HR (95% CI) in model 2 |                        | 1.19 (1.14–1.25)       | 1.07 (1.03–1.12)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       |
| HR (95% CI) in model 3 |                        | 1.22 (1.17–1.28)       | 1.07 (1.03–1.12)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       |
| HR (95% CI) in model 4 |                        | 1.34 (1.28–1.41)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       |

| Stroke                 |                        |                        |                        |                        |                        |
| No. of events          | 1,929                  | 2,017                  | 2,000                  | 2,045                  | 2,045                  |
| Follow-up duration, person-years | 210,045.40               | 2,292,568.95            | 3,616,300.87            | 2,565,780.53            | 2,565,780.53            |
| Incidence rate, /1,000 person-years | 9.18                       | 7.97                   | 7.94                   | 8.16                   | 8.38                   |
| HR (95% CI) in model 1 |                        | 1.12 (1.10–1.14)       | 1.06 (1.02–1.06)       | 1.04 (1.02–1.06)       | 1.04 (1.02–1.06)       |
| HR (95% CI) in model 2 |                        | 1.13 (1.10–1.15)       | 1.04 (1.02–1.06)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       |
| HR (95% CI) in model 3 |                        | 1.13 (1.11–1.16)       | 1.05 (1.03–1.07)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       |
| HR (95% CI) in model 4 |                        | 1.13 (1.11–1.16)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       | 1.10 (1.05–1.15)       |

| All-cause death        |                        |                        |                        |                        |                        |
| No. of events          | 7,330                  | 12,470                 | 59,219                 | 79,571                 | 50,784                 |
| Follow-up duration, person-years | 327,856.40               | 2,600,442.28           | 4,111,872.57           | 2,924,160.65           | 1,483,916.34           |
| Incidence rate, /1,000 person-years | 30.82                      | 22.77                  | 19.35                  | 17.37                  | 16.57                  |
| HR (95% CI) in model 1 |                        | 1.07 (1.05–1.09)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       |
| HR (95% CI) in model 2 |                        | 1.07 (1.05–1.09)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       |
| HR (95% CI) in model 3 |                        | 1.07 (1.05–1.09)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       |
| HR (95% CI) in model 4 |                        | 1.07 (1.05–1.09)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       | 1.01 (1.00–1.02)       |

Model 1: adjusted for age, sex, body mass index, current smoking, heavy alcohol consumption, regular exercise, low-income status, diabetes, hypertension, and statin use; Model 2: adjusted for Model 1 plus Charlson Comorbidity Index; Model 3: adjusted for model 2 plus triglyceride level; Model 4: adjusted for Model 3 plus high-density lipoprotein-cholesterol level. To account for the changes in LDL-C level and statin use during the follow-up period, a time-dependent Cox regression analysis was performed calculating the HRs for outcomes. HR, hazard ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol.